Prostate Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc

Prostate Cancer Pipeline constitutes 80+ key companies continuously working towards developing 80+ Prostate Cancer treatment therapies, analyzes DelveInsight.

Prostate Cancer Overview:

Prostate cancer occurs when cells in the prostate gland begin to grow uncontrollably. The prostate, which is unique to males, produces some of the fluid found in semen. The primary cause of prostate cancer is changes in DNA, which are triggered by mutations. It is usually diagnosed once the cancer has advanced and symptoms become noticeable, but early screenings can help detect it before symptoms appear. Due to the prostate's proximity to the urethra and bladder, urinary problems are common as the cancer develops. Depending on the tumor's size and location, it may press on or narrow the urethra, making urination more difficult. Early signs of prostate cancer include painful or burning urination, difficulty urinating, trouble starting or stopping urination, increased nighttime urination, loss of bladder control, and a weaker urine flow.

Request for a detailed insights report on Prostate Cancer pipeline insights @ https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Prostate Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Prostate Cancer Therapeutics Market.

Key Takeaways from the Prostate Cancer Pipeline Report

DelveInsight's Prostate Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Prostate Cancer treatment.
In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx® and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
In the same month, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
In July 2024, the ARANOTE trial demonstrated that NUBEQA® combined with androgen deprivation therapy (ADT) significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
Also in July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for mCRPC.
In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 combined with Abiraterone for mCRPC.
In May 2024, Fusion Pharmaceuticals initiated the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.
In April 2024, Astellas Pharma received European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
In the same month, FibroGen announced positive Phase 1 trial results for FG-3246 in mCRPC.
On February 12, 2024, BioXcel Therapeutics, Inc. revealed that the FDA granted Fast Track designation for BXCL701 with a checkpoint inhibitor (CPI) to treat metastatic small cell neuroendocrine prostate cancer (SCNC) in patients progressing on chemotherapy, allowing for expedited development and review.
On November 16, 2023, the FDA approved enzalutamide (Xtandi) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence.
Key Prostate Cancer companies such as Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, Cellbion Co., Ltd., and others are evaluating new drugs for Prostate Cancer to improve the treatment landscape.
Promising Prostate Cancer pipeline therapies in various stages of development include Niraparib, ZEN 3694, Ladiratuzumab vedotin, FOR46, REGN5678, and others.

Prostate Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Prostate Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prostate Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Prostate Cancer market.

Download our free sample page report on Prostate Cancer pipeline insights @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Prostate Cancer Emerging Drugs

Niraparib: Janssen Research & Development
ZEN 3694: Zenith Epigenetics
Ladiratuzumab vedotin: Seagen
FOR46: Fortis Therapeutics
REGN5678: Regeneron Pharmaceuticals

Prostate Cancer Companies

Around 140+ major companies are working on developing therapies for prostate cancer. Among these, Janssen Research & Development has some of the most advanced drug candidates for prostate cancer, currently in Phase III.

DelveInsight's report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Prostate Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Prostate Cancer Therapies and Key Companies: Prostate Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Prostate Cancer Pipeline Therapeutic Assessment
• Prostate Cancer Assessment by Product Type
• Prostate Cancer By Stage
• Prostate Cancer Assessment by Route of Administration
• Prostate Cancer Assessment by Molecule Type

Download Prostate Cancer Sample report to know in detail about the Prostate Cancer treatment market @ Prostate Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Prostate Cancer Current Treatment Patterns
4. Prostate Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Prostate Cancer Late-Stage Products (Phase-III)
7. Prostate Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Prostate Cancer Discontinued Products
13. Prostate Cancer Product Profiles
14. Prostate Cancer Key Companies
15. Prostate Cancer Key Products
16. Dormant and Discontinued Products
17. Prostate Cancer Unmet Needs
18. Prostate Cancer Future Perspectives
19. Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Prostate Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.